The search for a better vaccine has long been a challenge for scientists and healthcare professionals. But a new breakthrough could offer a potential solution: mRNA-based vaccines delivered in Lipid Nanoparticles (LNPs). By encapsulating and delivering antigen-expressing mRNA, LNPs could revolutionize the development and upscaling of vaccines, providing a more efficient and effective method of protection against disease. In this blog post, we explore the potential of LNPs as the answer to better vaccines.
Lipid Nanoparticles: Magic in a Bunch of Lipids.
Lipid nanoparticles (LNPs) are small particles made of lipid molecules and other components. They are usually between 50 and 1000 nanometers in size and can be used to encapsulate and deliver a wide variety of molecules. In the past, LNPs have been used to deliver drugs, vaccines, and genetic materials like mRNA, siRNA, and plasmid DNA. The main components of LNPs are lipids, which form protective layers around the molecules that need to be delivered. These layers not only help protect the molecule from degradation but also facilitates delivering to its site of action, the cells (1, 2).
Understanding the Role of Ionizable Lipids in the Effective Delivery of Nucleic Acids.
LNPs have proven to be very effective in encapsulating and delivering mRNA-based vaccines, thanks to the cationic/ionizable lipid component. Alongside these positively charged lipids, LNPs are composed of other lipid ingredients, typically including helper lipids, cholesterol, and PEG. What makes ionizable lipids one of the most crucial components is their ability to alter their charge depending on the surrounding environment.
For instance, they are positively charged at low pH; a property employed to facilitate interaction with and encapsulation of the negatively charged mRNA during the formulation stage. When in physiological pH, these lipids become neutrally charged; reducing the potential toxicity of the platform and aiding in increasing its circulation time. Once these particles transport to cells in a process called endocytosis, the acidic environment of endosomes switches the charge on these lipids to positive, allowing them to electrostatically pin the endosomal membrane and aiding in the escape of the antigen-expressing mRNA to its site of action, the cytoplasm (3, 4).
Lipid Nanoparticles: A Versatile and Upscaleable Solution for Rapid Vaccine Deployment.
As discussed, LNPs are extremely effective at encapsulating and delivering mRNA vaccine payloads, allowing for efficient translation in the cells of a vaccine recipient. This enabled the rapid development of several vaccines against SARS-CoV-2, including those from Pfizer/BioNTech, Moderna, and AstraZeneca. In addition to the success of mRNA vaccines against COVID-19, LNPs are being investigated for other diseases, such as influenza, CMV infection, AIDS, and cancer (5, 6).
Lipid nanoparticles offer a number of advantages over older conventional approaches, including swift deployment, improved immunogenicity, and greater flexibility when it comes to formulation. The flexibility of LNPs allows for the delivery of various types of antigens, including mRNA-based vaccines. This is a significant benefit as mRNA-based vaccines can be developed and produced rapidly in comparison to traditional ones, resulting in faster response times in the event of an outbreak. Additionally, this next-generation approach allows for the production of specific antigens that were deemed very challenging to upscale. In contrast, LNPs are upscalable, making them suitable for mass production. This translates to rapid deployment to address public health concerns on a large scale. Overall, LNPs offer a number of advantages over other approaches to vaccine development and could be an important part of any successful RNA/DNA vaccine program (7, 8)
Addressing the Challenges of Developing Lipid Nanoparticle-Based Vaccines
Though promising, there are many obstacles to producing the mRNA-based vaccine and LNP for widespread use. These obstacles include precisely controlling particle size distribution, ensuring process repeatability and scalability, meeting regulatory requirements (such as cGMP regulations), and tackling sterile filtration challenges. This requires the implementation of stringent manufacturing processes that ensure process repeatability and scalability. Additionally, meeting cGMP compliance standards is of paramount importance to ensure the safety and efficacy of the products. Given the recency of its implementation in the clinics, the challenges of developing and upscaling lipid nanoparticle-based vaccines may seem daunting but with the help of experienced experts such as those at Prorenata Biotech, these challenges can be successfully addressed (5, 7) .
Prorenata Biotech Offers Comprehensive Support to Develop Your Next Vaccine.
At prorenata Biotech, we understand the challenges of developing and upscaling lipid nanoparticle-based vaccines. Our experienced team of scientists offers comprehensive support to help you progress through the development process. The services we offer include formulation optimization, process development, analytical method development and validation, and GLP/GMP manufacturing.
As we provide customized services tailored to meet your specific needs and timelines, we are committed to helping you achieve the best results in the most efficient way possible. Learn more about our capbilities how we can help you develop your next vaccine by clicking here.
- Musielak E, Feliczak-Guzik A, Nowak I. Synthesis and potential applications of lipid nanoparticles in medicine. Materials. 2022;15(2):682.
- Aldosari BN, Alfagih IM, Almurshedi AS. Lipid nanoparticles as delivery systems for RNA-based vaccines. Pharmaceutics. 2021;13(2):206.
- Schlich M, Palomba R, Costabile G, Mizrahy S, Pannuzzo M, Peer D, et al. Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles. Bioengineering & Translational Medicine. 2021;6(2).
- Han X, Zhang H, Butowska K, Swingle KL, Alameh M-G, Weissman D, et al. An ionizable lipid toolbox for RNA delivery. Nature Communications. 2021;12(1).
- He Q, Gao H, Tan D, Zhang H, Wang J-zhi. MRNA cancer vaccines: Advances, trends and challenges. Acta Pharmaceutica Sinica B. 2022;12(7):2969–89.
- Barbier AJ, Jiang AY, Zhang P, Wooster R, Anderson DG. The clinical progress of mrna vaccines and immunotherapies. Nature Biotechnology. 2022;40(6):840–54.
- Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mrna delivery. Nature Reviews Materials. 2021;6(12):1078–94.
- Verbeke R, Lentacker I, De Smedt SC, Dewitte H. The dawn of mrna vaccines: The COVID-19 case. Journal of Controlled Release. 2021;333:511–20.